Mercy Research

St Louis, Missouri 65804

0 studies enrolling now · 13 studies all time

What they study most

Aortic Aneurysm, Abdominal, Atrial Fibrillation, Cardiovascular Disease, Coronary Heart Disease (CHD), Covid19, Migraine, Migraine Headache, Non-Muscle Invasive Bladder Neoplasms, Paroxysmal Supraventricular Tachycardia, Relapsing Multiple Sclerosis, SARS-CoV-2 Infection, Stroke

Studies at this site

• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine — Running, not enrolling
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation — Completed
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine — Completed
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache — Completed
• Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation — Completed
• Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms — Running, not enrolling
• Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). — Stopped early
• A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 — Stopped early
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early